https://www.selleckchem.com/pr....oducts/Erlotinib-Hyd
60, p = 0.01). NHB experienced the fastest decline in ESCC mortality (APC = - 4.53, p 0.001) yet maintained the highest mortality at the end of the study period. Proportions of late stage disease increased overall by 18.5 and 24.5 percentage points for EAC and ESCC respectively; trends varied by race/ethnicity. We found notable differences in trends in EAC and ESCC mortality and stage at diagnosis by race/ethnicity. Stage migration resulting from improvements in diagnosis and treatment may partially explain recent t
Like
Comment
Share
